Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens

Annals of Thoracic Surgery

Volumn 62, Issue 6, 1996, Pages 1659-1667

  Lemmer Jr , John H ^a   Dilling, Emery W ^b   Morton, Jeremy R ^b   Rich, Jeffrey B ^b   Robicsek, Francis ^b   Bricker, Donald L ^b   Hantler, Charles B ^b   Copeland III, Jack G ^b   Ochsner, John L ^b   Daily, Pat O ^b   Whitten, Charles W ^b   Noon, George P ^b   Maddi, Rosemarie ^b  

^a Northwest Surgical Associates   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 10544236908     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(96)00451-1     Document Type: Article

References (23)

1. 1. Bidstrup BP, Royston DM, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-72.
2. 2. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-8.
3. 3. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994;107:543-53.
4. 4. Davis R, Whittington R. Aprotinin: a review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995;49:954-83.
5. 5. Schönberger JPAM, Everts PAM, Ercan H, et al. Low-dose aprotinin in internal mammary artery bypass operations contributes to important blood saving. Ann Thorac Surg 1992;54:1172-6.
6. 6. Liu B, Tengborn L, Larson G, et al. Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations. Ann Thorac Surg 1995;59:1534-40.
7. 7. Levy JH, Pifarre R, Schaff HV, et al. A multicenter double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236-44.
8. 8. Blackburn H, Keys A, Simonson E. The electrocardiogram in population studies: a classification system. Circulation 1960; 21:1160-75.
9. 9. Guiteras Val P, Pelletier LC, Hernandez MG, et al. Diagnostic criteria and prognosis of perioperative myocardial infarction following coronary bypass. J Thorac Cardiovasc Surg 1983;86:878-86.
10. 10. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-97.
11. 11. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993;55:971-6.
12. 12. Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994;107:554-61.
13. 13. Lass M, Welz A, Kochs M, et al. Aprotinin in elective primary bypass surgery: graft patency and clinical efficacy. Eur J Cardiothorac Surg 1995;9:206-10.
14. 14. Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CRH. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 1991;51:936-41.
15. 15. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 1995;59:132-6.
16. 16. Feindt PR, Walcher S, Volkmer I, et al. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 1995;60:1076-80.
17. 17. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorto-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;55:147-53.
18. 18. Royston D. Intraoperative coronary thrombosis: can aprotinin be incriminated? J Cardiothorac Vasc Anesth 1994;8: 137-41.
19. 19. Dietrich W, Dilthey G, Spannagl M, et al. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite-and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology 1995;83:679-89.
20. 20. Levy JH, Bailey JM, Salmenperä M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994;80:1013-8.
21. 21. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Anesth 1992;6:76-100.
22. 22. Umbrain V, Christiaens F, Camu F. Intraoperative coronary thrombosis: can aprotinin and protamine be incriminated? J Cardiothorac Vasc Anesth 1994;8:198-201.
23. 23. Kalangos A, Tayyareci G, Prêtre R, Di Dio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994;8:651-6.